MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

January 17, 2025

Ryan Haumschild, PharmD, MS, MBA, CPEL
John Allan, MD

Opinion

Video

Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing epcoritamab and glofitamab that may influence therapy selection.

EP: 1.ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas

EP: 2.Emerging Data for Odronextamab in DLBCL

EP: 3.Sequencing Consequences for Earlier Line Use of Bispecifics in B-Cell Lymphomas

EP: 4.Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas

EP: 5.ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas

Now Viewing

EP: 6.MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas

Video content above is prompted by the following:

How do you use comparative data from MAIC analyses to guide treatment decisions between available bispecific therapies?
What do the results of the MAIC comparing epcoritamab and glofitamab suggest about the relative differences of these agents, and how might these influence therapy selection?